Introducing Polsky On Demand, a new online portal of Polsky's world-class business and entrepreneurship workshops
Learn more

In Era of Research Cuts, Romance Blossoming Much Earlier Between Universities and Big Pharma

Engineering new pharmaceuticals is risky, achingly slow and astronomically expensive. While the estimates of how much it costs to get a drug into patients’ hands vary and are often disputed, Tufts University pegs the figure at north of $2.5 billion. In search of better ways to defray those costs and speed the path to success, Chicago’s elite research universities are partnering with the major pharmaceutical companies, ushering in a new era of early-phase collaboration. Read more.

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.

Accept